Latest Insider Transactions at Iovance Biotherapeutics, Inc. (IOVA)
This section provides a real-time view of insider transactions for Iovance Biotherapeutics, Inc. (IOVA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IOVANCE BIOTHERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IOVANCE BIOTHERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Raj K. Puri Chief Regulatory Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,759
-2.36%
|
$26,313
$7.84 P/Share
|
|
Dec 16
2024
|
Raj K. Puri Chief Regulatory Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+4.98%
|
-
|
|
Dec 02
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,982
-3.07%
|
$17,838
$9.07 P/Share
|
|
Dec 02
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+5.7%
|
-
|
|
Dec 02
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,784
-3.01%
|
$16,056
$9.07 P/Share
|
|
Dec 02
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,516
+5.6%
|
-
|
|
Dec 02
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,426
-2.06%
|
$39,834
$9.07 P/Share
|
|
Dec 02
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+4.63%
|
-
|
|
Nov 12
2024
|
Ryan D Maynard Director |
SELL
Open market or private sale
|
Direct |
50,000
-86.96%
|
$500,000
$10.06 P/Share
|
|
Nov 12
2024
|
Ryan D Maynard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+46.51%
|
$350,000
$7.45 P/Share
|
|
Oct 14
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-2.5%
|
$12,852
$9.77 P/Share
|
|
Oct 14
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+4.68%
|
-
|
|
Oct 14
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-2.3%
|
$12,852
$9.77 P/Share
|
|
Oct 14
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+4.33%
|
-
|
|
Oct 14
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-4.15%
|
$79,659
$9.77 P/Share
|
|
Oct 14
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+8.91%
|
-
|
|
Sep 03
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,874
-10.34%
|
$138,740
$10.85 P/Share
|
|
Sep 03
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,345
+16.02%
|
-
|
|
Sep 03
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
24,339
-6.0%
|
$243,390
$10.85 P/Share
|
|
Sep 03
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
57,292
+11.94%
|
-
|
|
Sep 03
2024
|
Jean Marc Bellemin Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,891
-28.83%
|
$118,910
$10.85 P/Share
|
|
Sep 03
2024
|
Jean Marc Bellemin Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,438
+36.24%
|
-
|
|
Sep 03
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,675
-10.96%
|
$136,750
$10.85 P/Share
|
|
Sep 03
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,954
+16.71%
|
-
|
|
Jul 15
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-3.35%
|
$11,424
$8.68 P/Share
|
|
Jul 15
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+6.2%
|
-
|
|
Jul 15
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-3.02%
|
$11,424
$8.68 P/Share
|
|
Jul 15
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+5.61%
|
-
|
|
Jul 15
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-5.26%
|
$70,808
$8.68 P/Share
|
|
Jul 15
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,835
+11.02%
|
-
|
|
Jun 03
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,784
-4.29%
|
$14,272
$8.37 P/Share
|
|
Jun 03
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,516
+7.8%
|
-
|
|
Jun 03
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,982
-4.27%
|
$15,856
$8.37 P/Share
|
|
Jun 03
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,906
+7.75%
|
-
|
|
Jun 03
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,426
-2.92%
|
$35,408
$8.37 P/Share
|
|
Jun 03
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+6.42%
|
-
|
|
Apr 15
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,427
-3.62%
|
$15,697
$11.89 P/Share
|
|
Apr 15
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+6.65%
|
-
|
|
Apr 15
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,427
-3.24%
|
$15,697
$11.89 P/Share
|
|
Apr 15
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+6.01%
|
-
|
|
Apr 15
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-5.89%
|
$97,361
$11.89 P/Share
|
|
Apr 15
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+12.18%
|
-
|
|
Mar 04
2024
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
11,449
-8.13%
|
$183,184
$16.96 P/Share
|
|
Mar 04
2024
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
41,662
+22.83%
|
-
|
|
Mar 04
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,053
-16.36%
|
$128,848
$16.96 P/Share
|
|
Mar 04
2024
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,623
+24.09%
|
-
|
|
Mar 04
2024
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,287
-16.59%
|
$116,592
$16.96 P/Share
|
|
Mar 04
2024
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,061
+24.25%
|
-
|
|
Feb 20
2024
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Direct |
250,000
+43.85%
|
$2,250,000
$9.15 P/Share
|
|
Feb 20
2024
|
Iain D. Dukes Director |
BUY
Open market or private purchase
|
Direct |
32,000
+37.21%
|
$288,000
$9.15 P/Share
|